絞り込み

16636

広告

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

著者 Bertranou E , Bodnar C , Dansk V , Greystoke A , Large S , Dyer M
J Med Econ.2017 Sep 07 ; ():1-17.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (96view , 0users)

Full Text Sources

Medical

Miscellaneous

This study presents the cost-utility analysis that was developed to inform the NICE health technology assessment of osimertinib versus platinum-based doublet chemotherapy (PDC) in patients with EGFR-T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.
PMID: 28880737 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード